Denali Therapeutics Inc. DNLI Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -45.7%-8.3pp | -37.4%-23.4pp | -14%+18.5pp | -32.5%-5.0pp | |
| Return on invested capital | -56.8%-9.5pp | -47.3%-25.9pp | -21.4%+20.8pp | -42.2%-1.2pp | |
| Efficiency | |||||
| Asset turnover | 0×— | 0×-0.3× | 0.3×+0.2× | 0.1×0.0× | |
| Liquidity | |||||
| Current ratio | 9.2×+0.7× | 8.5×-5.2× | 13.6×+9.9× | 3.8×+1.4× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | |||||
| Book value per share | $5.87-21.5% | $7.48-0.4% | $7.50-9.6% | $8.30+4.9% | |
| Valuation | |||||
| Market capitalization | $2.58B-12.1% | $2.93B-1.1% | $2.97B-21.5% | $3.78B-30.7% | |
| Price / book | 2.5×+0.2× | 2.4×-0.5× | 2.9×-0.7× | 3.6×-2.0× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Denali Therapeutics Inc.'s ratios come from?
- Every ratio is computed from Denali Therapeutics Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.